Efficacy and safety of quinapril 40 mg in uncontrolled hypertension. victoria study

Abstract

Last Joint National Committee (JNC) recommendations are stricter, especially with hypertensive patients with associated risk factors. Our objective is to determine if the convenience in dosage range in monotherapy could improve hypertensive control. Victoria Study was designed in order to evaluate the efficacy and safety of Quinapril 40 mg in 22,000 patients treated during 8 weeks. The study began in March 1999. In November 1999 we obtained the information of 2012 patients, 54% males, 15% diabetics and 10% with cardiovascular disease. Most of them (71%) were previously treated with anti-hypertensive treatment. 1% had controlled sistolic blood pressure (SBP) (<140 mmHg or <135 mmHg, depending on the risk factors) and 6% had controlled diastolic blood pressure (DBP) (<90 mmÇHg or <85 mmHg depending on the risk factors) with mean values of SBP 165 ± 16 and DBP 98 ± 9 (mmHg ± SD). After 2 months of treatment with Quinapril 40 mg, the percentage of controlled blood pressure values (<140/90 mmHg or 130/85 mmHg) increased up to 28% in SBP and 65% in DBP. Quinapril 40 mg was well tolerated and no relevant adverse events were detected. We conclude that Quinapril 40 is able to control blood pressure in hypertensive population previously treated and uncontrolled. The number of patients controlled were 65% for DBP and 28% for SBP, in patients previously treated with other anti-hypertensive medication but without reaching the minimum JNC recommendations (<140/90 mmHg).